Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VNRX
VNRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VNRX News
VolitionRx Receives NYSE Compliance Notice
6d ago
seekingalpha
Venus Concept Inc. Announces Voluntary Delisting from NASDAQ to Cut Compliance Costs
Jan 21 2026
Globenewswire
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
Jan 20 2026
PRnewswire
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
Jan 20 2026
Newsfilter
VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test
Jan 16 2026
Newsfilter
VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test
Jan 16 2026
PRnewswire
VolitionRx Secures $2 Million Financing Agreement with Lind Global Asset Management
Jan 08 2026
PRnewswire
VolitionRx Secures $2 Million Financing Agreement with Lind Global Asset Management
Jan 08 2026
Newsfilter
VolitionRx Launches World's First Feline Liquid Biopsy Test for Cancer Detection
Jan 08 2026
PRnewswire
Bolt Projects Raises FY2026 Sales Guidance to $11 Million
Dec 29 2025
Benzinga
VolitionRx Secures First Lung Cancer Nu.Q® Order and Joins $7.3M Sepsis Detection Program
Dec 17 2025
PRnewswire
Volition Achieves 180-Fold Enrichment in Liquid Biopsy, Solving Cancer Detection Challenge
Dec 11 2025
Newsfilter
VolitionRx Presents Nu.Q® Cancer Assays Advancements at Lung Cancer Conference
Dec 08 2025
PRnewswire
VolitionRx Unveils Nu.Q® Cancer Assays for Enhanced Lung Cancer Management and Prognosis
Dec 08 2025
Newsfilter
D. Boral Capital Reiterates Buy Rating on VolitionRX with $5 Price Target Intact
Nov 26 2025
Benzinga
VolitionRx Makes First Sale of Nu.Q® Cancer Assays to Leading French Cancer Center
Nov 25 2025
Newsfilter
Show More News
